NCT07322263 2026-04-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Recruiting
Clinical Trials
124 trialsNCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05239624 2026-04-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05406713 2026-04-08
Pembrolizumab in Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Active not recruiting
NCT03093922 2026-04-07
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02845323 2026-04-06
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT07506057 2026-04-01
SHIELD
China Medical University, China
Phase 2 Recruiting
NCT05226117 2026-03-27
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer
IRCCS San Raffaele
Phase 2 Completed
NCT05923190 2026-03-19
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT07460245 2026-03-10
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT05335941 2026-03-04
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04848519 2026-02-19
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
Phase 2 Active not recruiting
NCT07221942 2026-02-19
IMPROEV
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05868265 2026-02-17
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT04701918 2026-01-22
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT03744793 2026-01-09
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT06511648 2025-12-19
SOGUG-NEOWIN
Spanish Oncology Genito-Urinary Group
Phase 2 Recruiting
NCT07241793 2025-12-18
TRAIN-UC-01
Sun Yat-sen University
Phase 2 Recruiting
NCT00756639 2025-12-17
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT03914794 2025-10-03
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT04678362 2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2 Recruiting
NCT06184516 2025-09-15
Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy
University of Florida
Phase 2 Recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT06983210 2025-08-14
GRAPE
Nagoya University
Phase 2 Recruiting
NCT01261728 2025-08-08
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06356155 2025-07-29
NEPTUNE
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT07043972 2025-07-20
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
Phase 2 Recruiting
NCT02717156 2025-06-05
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors
University of Southern California
Phase 2 Active not recruiting
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT04602078 2025-04-24
AUREA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT04294277 2025-04-18
PEGASUS
European Association of Urology Research Foundation
Phase 2 Terminated
NCT06682728 2025-03-26
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
University of California, Irvine
Phase 2 Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT02662309 2025-03-10
ABACUS
Queen Mary University of London
Phase 2 Completed
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03240016 2025-01-16
ABLE
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03272217 2025-01-07
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03534804 2024-11-26
PemCab
University of Utah
Phase 2 Completed
NCT03486197 2024-11-20
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Phase 2 Terminated
NCT03658304 2024-11-05
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
Phase 2 Completed
NCT05229614 2024-08-21
ICONIC
CNAO National Center of Oncological Hadrontherapy
Phase 2 Recruiting
NCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT05574504 2024-08-01
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
Phase 2 Withdrawn